These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 27600150)

  • 1. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
    Fleseriu M; Castinetti F
    Pituitary; 2016 Dec; 19(6):643-653. PubMed ID: 27600150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cushing's disease: adrenal steroidogenesis inhibitors.
    Pivonello R; Simeoli C; Di Paola N; Colao A
    Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
    Varlamov EV; Han AJ; Fleseriu M
    Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome.
    Daniel E; Newell-Price JD
    Eur J Endocrinol; 2015 Jun; 172(6):R263-80. PubMed ID: 25637072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
    Perosevic M; Tritos NA
    Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approach to the Patient Treated with Steroidogenesis Inhibitors.
    Castinetti F; Nieman LK; Reincke M; Newell-Price J
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment.
    Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
    J Clin Endocrinol Metab; 2021 Mar; 106(4):e1618-e1630. PubMed ID: 33399817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the role of medical therapy in adrenal-dependent Cushing's syndrome?
    Braun LT; Reincke M
    Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101376. PubMed ID: 32063487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
    Lau D; Rutledge C; Aghi MK
    Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levoketoconazole: a novel treatment for endogenous Cushing's syndrome.
    Fleseriu M; Auchus RJ; Pivonello R; Salvatori R; Zacharieva S; Biller BMK
    Expert Rev Endocrinol Metab; 2021 Jul; 16(4):159-174. PubMed ID: 34380370
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
    Engelhardt D; Weber MM
    J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
    Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome.
    Valassi E; Aulinas A; Glad CA; Johannsson G; Ragnarsson O; Webb SM
    Clin Endocrinol (Oxf); 2017 Nov; 87(5):433-439. PubMed ID: 28665508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples.
    Fleseriu M; Biller BMK
    Pituitary; 2022 Dec; 25(6):795-809. PubMed ID: 36002784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs in the medical treatment of Cushing's syndrome.
    Schteingart DE
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole.
    Feelders RA; Hofland LJ; de Herder WW
    Neuroendocrinology; 2010; 92 Suppl 1():111-5. PubMed ID: 20829630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in medical therapies for Cushing's syndrome.
    Tritos NA; Biller BM
    Discov Med; 2012 Feb; 13(69):171-9. PubMed ID: 22369976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenally Directed Medical Therapies for Cushing Syndrome.
    Tritos NA
    J Clin Endocrinol Metab; 2021 Jan; 106(1):16-25. PubMed ID: 33118025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.
    Pivonello R; Ferrigno R; De Martino MC; Simeoli C; Di Paola N; Pivonello C; Barba L; Negri M; De Angelis C; Colao A
    Front Endocrinol (Lausanne); 2020; 11():648. PubMed ID: 33363514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological management of severe Cushing's syndrome: the role of etomidate.
    Pence A; McGrath M; Lee SL; Raines DE
    Ther Adv Endocrinol Metab; 2022; 13():20420188211058583. PubMed ID: 35186251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.